FOR MORE INFORMATION PLEASE CONTACT US
In order to be able to design our website in the best possible way and to continuously improve it, we are using cookies.
By continuing to use our website, you permit the use of cookies. More information can be found in our data protection rules.
We may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.
Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to deliver the website, refusing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.
We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.
We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.
We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.
Google Webfont Settings:
Google Map Settings:
Google reCaptcha Settings:
Vimeo and Youtube video embeds:
Tagworks Pharmaceuticals Appoints Ken Mills as Chief Executive Officer
Atriva Therapeutics Announces Exclusive Letter Agreement for Reverse Takeover Transaction with Biocure Technology
Tagworks Pharmaceuticals Announces $65 Million in Series A Financing to Advance Click-to-Release Therapeutics
Atriva Therapeutics appoints Christian Pangratz as Chief Executive Officer, implementing planned management change
Hemispherian Secures EUR 10M in Financing from the European Innovation Council (EIC) Accelerator Program
Atriva Therapeutics announces Topline Results from the Proof of Concept (POC) / Phase 2a RESPIRE study (zapnometinib) in patients hospitalized with COVID-19
Xenikos Enrolls First Patient in Global Pivotal Phase 3 Study Evaluating T-Guard® in Patients with Steroid-Refractory Acute Graft-Versus-Host Disease
Hemispherian raises seed funding for novel cancer therapeutics
Atriva Therapeutics receives U.S. FDA Orphan Drug Designation for Zapnometinib to treat Hantavirus Infections
APTAMER GROUP: ADMISSION TO TRADING ON AIM & FIRST DAY OF DEALINGS
Atriva Therapeutics strengthens advisory board with Piet Wigerinck
Atriva Therapeutics’ lead candidate Zapnometinib shows substantial efficacy against SARS-CoV-2
Xenikos Secures €40 Million in Convertible Debt Financing, Veloxis Pharmaceuticals Joins as Strategic Investor
Spahn/Karliczek: Weiterer Schub zur Entwicklung und Herstellung von versorgungsnahen Arzneimitteln gegen COVID-19
Xenikos Announces T-Guard® Phase 3 Clinical Update and Outlines 2021-2022 Corporate Objectives
Byondis Announces Positive Topline Results of Pivotal Phase III TULIP® Study in Patients With HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer
Atriva Therapeutics to Speed up Development of COVID-19 Drug with Federal Funding
Atriva Therapeutics Announces Changes to Management
Atriva Therapeutics Doses First Patient in Phase II RESPIRE trial in COVID-19
Aptamer Group, Mologic Ink Deal to Develop Coronavirus Antigen Test
LightOx: Developing new therapeutic solutions to improve patients function and long term outcomes with oral cancer
Atriva Therapeutics Announces Changes to Advisory Board
Atriva Therapeutics obtains approval from German authorities for Phase II trial in COVID-19 patients, led by Charité Clinic in Berlin
Initiative BEAT-COV fordert Unterstützung für Entwicklung und Produktion neuer, innovativer COVID-19-Medikamente
Germany: EIB backs Atriva Therapeutics with €24 million for the development of a potential COVID-19 treatment
Atriva announces closing of € 8.6 million ($ 10.2 million) oversubscribed convertible loan
Publication in PNAS unveils molecular pathway required for influenza virus replication with large potential as an antiviral drug target
Aptamer Group on BBC Look North 17th June 2020
LightOx May 2020
Atriva Therapeutics to Develop ATR-002 for Treatment of Patients with COVID-19 in Phase II Study
Therapieansätze gegen das Wuhan-Virus Deutsche Forscher entwickeln Impfstoffe gegen Coronaviren
Atriva Therapeutics to take part in three major conferences in San Francisco, USA, in the upcoming week
Atriva Therapeutics Reports Results of ATR-002 Phase I Clinical Trial
Xenikos receives FDA Fast Track designation for T-Guard(R) for treating steroid-refractory acute graft-versus-host disease
Britten kopen farmabedrijf Synthon uit Nijmegen
Dringend gezocht: nieuwe antibiotica
Xenikos announces IND clearance by the FDA for a pivotal Phase 3 trial using T-Guard® for treating steroid-refractory acute GVHD
Atriva Therapeutics Starts Clinical Development of Novel Host-Targeting Antiviral ATR-002 Against Influenza
LightOx appoints experienced Non-Executive Directors and closes investment round
Aptamer Therapeutics and Cancer Research UK announce partnership for drug development programme
Galapagos steekt ruim €300 miljoen in zoektocht naar nieuwe medicijnen
Aanval op het bestverkochte medicijn ter wereld
De toenemende ongevoeligheid voor antibiotica is angstaanjagend